rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Integra LifeSciences Holdings Corporation

IART · Nasdaq

Health CareMedical DevicesNot moving yet

IART stood above a rising 150-day average in 17 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 11.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$102K
Insider sales, 12 months
$0
Officials’ trades on record
18
Institutions holding
196 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$132K$0$93KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

18 disclosed lines: House 15, Senate 1, executive 2; 6 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k30 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k26 Feb 2026filed 14 May 2026
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k18 Jun 2024filed 9 Jul 2024
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k5 Apr 2024filed 15 May 2024
Josh Gottheimer House: U.S. House ClerkNJ05boughtjoint$1k–$15k16 Oct 2023filed 11 Nov 2023
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k15 Sep 2023filed 15 Oct 2023
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k13 Jun 2023filed 11 Jul 2023
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k16 Oct 2020filed 5 Nov 2020
Josh Gottheimer House: U.S. House ClerkNJ05sold$1k–$15k15 Sep 2020filed 13 Oct 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k10 Mar 2020filed 16 Apr 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k10 Feb 2020filed 10 Mar 2020
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k3 Feb 2020filed 16 Mar 2020

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders196+12 on the quarter
New · exited46 · 33
Reported value$1.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202610,684,103$191.9M+364,934+3.5%
Rubric Capital Management LPunchanged · filed 14 Aug 20267,753,934$139.3M00.0%
Invesco Ltd.added · filed 14 Aug 20263,749,367$67.3M+263,764+7.6%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20263,743,093$67.2M+56,456+1.5%
MORGAN STANLEYadded · filed 13 Aug 20263,593,079$64.5M+8,924+0.2%
PARADIGM CAPITAL MANAGEMENT INCreduced · filed 13 Aug 20263,439,098$61.8M-573,600−14.3%
FULLER & THALER ASSET MANAGEMENT, INC.reduced · filed 12 Aug 20263,436,006$61.7M-93,398−2.6%
STATE STREET CORPadded · filed 7 Aug 20262,946,862$52.9M+60,306+2.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,946,173$52.9M+55,349+1.9%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20262,364,777$42.6M+249,522+11.8%
31 Mar 2023 – 30 Jun 2026
186215243Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

Chantal Veillon-Berteloot Company insiderEVP & CHRO · last 1 Sep 20260 · 0
Lea Daniels Knight Company insiderEVP & Chief Financial Officer · last 3 Jul 20260 · 0
Harvinder Singh Company insiderEVP & President, SS · last 1 Jul 20260 · 0
Jeffrey Mosebrook Company insiderSVP, Fin & Princ Acct Officer · last 1 Jul 20260 · 10
Robert T. Davis Jr. Company insiderEVP & President, TR&DT · last 1 Jul 20260 · 5
Michael J. McBreen Company insiderEVP & Chief Commercial Officer · last 1 Jun 20260 · 6
Stuart Essig Company insiderPresident and CEO · last 1 Jun 20261 · 67
Keith Bradley Company insiderDirector · last 9 May 20260 · 7
Barbara B. Hill Company insiderDirector · last 7 May 20264 · 0
Christian S. Schade Company insiderDirector · last 7 May 20260 · 4
Jeffrey A. Graves Company insiderDirector · last 7 May 20261 · 0
Renee Wonlai Lo Company insiderDirector · last 7 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202550.9%
Operating profit marginFY 2025 · to 31 Dec 2025-30.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-1.9%
Return on capital employedFY 2025 · to 31 Dec 2025-15.7%
Debt to equityFY 2025 · to 31 Dec 20250.70×
Share count trendFY 2025 · to 25 Feb 20261.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$235.0M
Free cash flowFY 2025 · to 31 Dec 2025−$31.1M

Analyst forecasts

No analyst forecasts yet.